Patents by Inventor Keivan Zandi

Keivan Zandi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250114389
    Abstract: Compounds, compositions and methods for preventing, treating or curing a coronavirus infection in human subjects or other animal hosts. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1, OC43, and SARS-CoV-2. In another embodiment, the methods are used to treat a patient infected with a Flavivirus, Picornavus, Togavirus, or Bunyavirus.
    Type: Application
    Filed: April 11, 2022
    Publication date: April 10, 2025
    Inventors: Raymond SCHINAZI, Franck AMBLARD, Mahesh KASTHURI, Nicolas BITEAU, Junxing SHI, Longhu ZHOU, Keivan ZANDI
  • Patent number: 12268723
    Abstract: Compounds, compositions and methods for preventing, treating or curing a coronavirus, picornavirus, and/or hepeviridae virus infection in human subjects or other animal hosts. Specific viruses that can be treated include enteroviruses. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1 (OC43), and SARS-CoV-2. In another embodiment, the methods are used to treat a patient co-infected with two or more of these viruses, or a combination of one or more of these viruses and norovirus.
    Type: Grant
    Filed: December 7, 2021
    Date of Patent: April 8, 2025
    Assignee: Emory University
    Inventors: Raymond F. Schinazi, Keivan Zandi, Franck Amblard
  • Publication number: 20240238323
    Abstract: Compounds, compositions and methods for preventing, treating or curing a coronavirus infection in human subjects or other animal hosts. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1 (OC43), and SARS-CoV-2. In another embodiment, the methods are used to treat a patient infected with a Flavivirus, Picornavus, Togavirus, or Bunyavirus.
    Type: Application
    Filed: April 11, 2022
    Publication date: July 18, 2024
    Inventors: Raymond Schinazi, Franck Amblard, HongWang Zhang, Keivan Zandi
  • Publication number: 20240216413
    Abstract: Compounds, compositions and methods for preventing, treating or curing a coronavirus infection in human subjects or other animal hosts. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1, OC43, and SARS-CoV-2. In another embodiment, the methods are used to treat a patient infected with a Flavivirus, Picornavus, Togavirus, or Bunyavirus.
    Type: Application
    Filed: April 11, 2022
    Publication date: July 4, 2024
    Applicant: Emory University
    Inventors: Raymond SCHINAZI, Franck AMBLARD, Zhe CHEN, Keivan ZANDI
  • Publication number: 20220273753
    Abstract: Compounds, compositions and methods for preventing, treating or curing a coronavirus, picornavirus, and/or hepeviridae virus infection in human subjects or other animal hosts. Specific viruses that can be treated include enteroviruses. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1 (OC43), and SARS-CoV-2. In another embodiment, the methods are used to treat a patient co-infected with two or more of these viruses, or a combination of one or more of these viruses and norovirus.
    Type: Application
    Filed: December 7, 2021
    Publication date: September 1, 2022
    Inventors: Raymond F. Schinazi, Keivan Zandi, Franck Amblard
  • Patent number: 11207370
    Abstract: Compounds, compositions and methods for preventing, treating or curing a coronavirus, picornavirus, and/or hepeviridae virus infection in human subjects or other animal hosts. Specific viruses that can be treated include enteroviruses. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1 (OC43), and SARS-CoV-2. In another embodiment, the methods are used to treat a patient co-infected with two or more of these viruses, or a combination of one or more of these viruses and norovirus.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: December 28, 2021
    Assignee: Emory University
    Inventors: Raymond F. Schinazi, Keivan Zandi, Franck Amblard
  • Publication number: 20210008150
    Abstract: Compounds, compositions and methods for preventing, treating or curing a coronavirus, picornavirus, and/or hepeviridae virus infection in human subjects or other animal hosts. Specific viruses that can be treated include enteroviruses. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1 (OC43), and SARS-CoV-2. In another embodiment, the methods are used to treat a patient co-infected with two or more of these viruses, or a combination of one or more of these viruses and norovirus.
    Type: Application
    Filed: June 5, 2020
    Publication date: January 14, 2021
    Inventors: Raymond F. Schinazi, Keivan Zandi, Franck Amblard
  • Publication number: 20160213647
    Abstract: Compositions and methods for inhibiting viral protein production, viral infection, and viral replication in a host or host cells infected with a virus (e.g., influenza, Junin, Chikungunya, Dengue, HIV, RHDV) by administering AR-12 and AR-12 analogs are provided.
    Type: Application
    Filed: January 27, 2016
    Publication date: July 28, 2016
    Inventors: Larry Schlesinger, Jacob Yount, Alexander Zukiwski, Stefan Proniuk, María Jesús Tuñón, Keivan Zandi